[Edaily Starin YUN GI BACK Reporter] The group aespa has once again proven its strong popularity in Japan by topping the Oricon charts with its first Japanese mini-album. Having successfully wrapped up their fan meetings and promotions for the new album, they are set to continue their global rise through a world tour. aespa (Photo: SM Entertainment) According to their agency, SM Entertainment, on the 25th, aespa’s first Japanese mini-album, “KISS N TELL,” ranked No. 1 on the Oricon Daily Album Chart for the 23rd. This achievement, coming from an original Japanese release, is seen as further confirmation of the group’s influence in the local market. The album features the title track “KISS N TELL,” as well as “Orbit Pop,” “Fangirl,” “Done with Rules,” “ATTITUDE” (the opening theme for the TV anime “KILL BLUE”), and “In Halo” (the OST for the drama “Love at First Bite)—for a total of six tracks. The album captures aespa’s unique personality and diverse musical style, garnering a positive response from local fans. Ahead of the album’s release, aespa held their second fan meeting, “MY-J presents aespa JAPAN FANMEETING 2026 ‘MY CLASSMaeTE,’” at Keio Arena in Tokyo, Japan, from the 18th to the 20th, where they debuted their new songs on stage for the first time. After building excitement for their comeback through performances and fan interactions, their album’s success has further proven their popularity in Japan. Using their activities in Japan as a springboard, aespa is set to kick off their global tour in earnest. After kicking off their new world tour, “SYNK: COMPLaeXITY,” at Seoul’s Gocheok Sky Dome on the 7th and 8th of next month, they plan to expand their tour to North and South America, Europe, and beyond to meet fans around the world.
The "Korea Expo," a comprehensive consumer goods trade show, opened on the 22nd at Magic Box in downtown Los Angeles and will run through the 24th. This marks the first time the Korea Expo—which debut…
SCL Science(246960)is accelerating its new drug development efforts, spearheaded by vaccines for liver and ovarian cancer. With the goal of submitting an Investigational New Drug (IND) application nex…
Korean small-cap pharma, biotech, and healthcare stocks moved in opposite directions on Oct. 22, as large-cap chipmakers weakened. Rokit Healthcare posted the steepest decline on the KOSDAQ, while in-…